Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Norvir Compulsory Licensing Would Take Several Years, NIH Says

This article was originally published in The Pink Sheet Daily

Executive Summary

NIH cannot grant Norvir patent licenses under the Bayh/Dole Act until Abbott has exhausted its appeals process, and follow-on products would have to gain standard FDA approval, the agency says. NIH expects to make a decision on whether to apply its "march-in" authority for the HIV product as soon as possible. The precedent established could have an immediate effect; NIH received a petition requesting the use of march-in rights for Pfizer's Xalatan.
Advertisement

Related Content

GSK To Supply Combivir For NIH-Funded AIDS Trial Following Rep. Waxman Letter
GSK To Supply Combivir For NIH-Funded AIDS Trial Following Rep. Waxman Letter
Abbott Norvir Cost Chart Misrepresents Therapeutic Dose, Price – FDA Warning Letter
Abbott Norvir Cost Chart Misrepresents Therapeutic Dose, Price – FDA Warning Letter
Norvir Federal Grants Were Roughly 1% Of Development Costs, Abbott Says
Norvir Federal Grants Were Roughly 1% Of Development Costs, Abbott Says
Abbott Norvir Pricing Needs Investigation By FTC, Senators Say
Abbott Norvir Pricing Needs Investigation By FTC, Senators Say

Topics

Advertisement
UsernamePublicRestriction

Register

PS059507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel